Impact of amyloidosis on outcomes after transcatheter aortic valve implantation
Article 2025 es
Authors
LG
Luigi Gerra
TB
Tommaso Bucci
SL
Steven Ho Man Lam
Abstract
1 min read
Among patients undergoing TAVI, those with amyloidosis are at a higher risk of adverse events, particularly HF, and have an increased risk of pacemaker implantation and stroke in the long-term.
Jeroen J. Bax, Victoria Delgado, Vinayak Bapat, Helmut Baumgartner, Jean Collet, Raimund Erbel, Christian W. Hamm, A. Pieter Kappetein, Jonathon Leipsic, Martin B. Leon, Philip MacCarthy, Nicolò Piazza, Philippe Pîbarot, William C. Roberts, Josep Rodés‐Cabau, Patrick W. Serruys, Martyn Thomas, Alec Vahanian, John G. Webb, José Luis Zamorano, Stephan Windecker
Nicolas M. Van Mieghem, Robert M. van der Boon, Rutger‐Jan Nuis, Carl Schultz, Robert‐Jan van Geuns, Patrick W. Serruys, A. Pieter Kappetein, Ron T. van Domburg, Peter P. de Jaegere
Robert M.A. van der Boon, Alaide Chieffo, Nicolas Dumonteil, Didier Tchetchè, Nicolas M. Van Mieghem, Gill Louise Buchanan, Olivier Vahdat, Bertrand Marcheix, Patrick W. Serruys, Jean Fajadet, Antonio Colombo, Didier Carrié, Ron T. van Domburg, Peter P.T. de Jaegere
Mohammad Abdelghani, Rafael Cavalcante, Yosuke Miyazaki, Robbert de Winter, Jan Tijssen, Rogério Sarmento‐Leite, José Armando Mangione, Alexandre Abizaid, Pedro A. Lemos, Patrick W. Serruys, Fabio de Brito
Discussion(0)
No comments yet. Be the first to comment.